[{"id":"ae2a0cef-0d7a-4179-8363-611253b7fb73","acronym":"","url":"https://clinicaltrials.gov/study/NCT01764022","created_at":"2021-01-18T07:45:21.346Z","updated_at":"2024-07-02T16:37:04.993Z","phase":"Phase 3","brief_title":"A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients","source_id_and_acronym":"NCT01764022","lead_sponsor":"Biocad","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification • PGR expression","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • HERtiCAD (trastuzumab biosimilar)"],"overall_status":"Completed","enrollment":" Enrollment 225","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 03/01/2015","primary_completion_date":" 03/01/2015","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2018-11-29"}]